Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PVCT $1.00 0.1368 +15.91%
BIND $8.80 0.9700 +12.39%
INCY $63.44 5.5700 +9.63%
CLSN $2.80 0.2400 +9.38%
ONCY $0.78 0.0620 +8.64%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

VICL $1.15 -0.0600 -4.96%
PPHM $1.53 -0.0600 -3.77%
APRI $1.57 -0.0600 -3.68%
DNDN $0.99 -0.0369 -3.58%
CNDO $1.74 -0.0600 -3.33%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

This Device Could Detect Dozens of Cancers With a Single Blood Test

(Wired) Oct 10, 2014 - Early detection, we’re often told, is the surest way to beat cancer. It’s the reason why, year after year, men and women of a certain age dutifully visit their doctors and undergo uncomfortable tests to screen for things like prostate and breast cancer.
read article 



Alchemia Enters Analysis Stage for mCRC Trial

(Australian Life Scientist) Oct 13, 2014 - Alchemia has entered the endpoint analysis phase for its pivotal phase III trial of HA-Irinotecan in metastatic colorectal cancer.
read article 



Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML

(Cancer Genetics) Oct 13, 2014 - Cancer Genetics, Inc. announced today that it has entered into a research collaboration with Columbia University researchers to identify more accurate diagnostic and prognostic markers for myelodysplastic syndromes (MDS), as well as novel therapies to target this class of bone marrow cancers.
read corporate press release 



Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma

(Yahoo! Finance) Oct 13, 2014 - Bristol-Myers Squibb Company, Pharmacyclics, Inc., and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® (nivolumab) in combination with IMBRUVICA® (ibrutinib).
read article 



Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma

(CNNMoney) Oct 13, 2014 - Dynavax Technologies Corporation today announced initiation of a phase 1/2 clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor ("TLR") 9 agonist, in adults with untreated low-grade B-cell lymphoma.
read article 



New Computational Approach Finds Gene That Drives Aggressive Brain Cancer

(CUMC) Oct 9, 2014 - Using an innovative algorithm that analyzes gene regulatory and signaling networks, Columbia University Medical Center (CUMC) researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer.
read press release 



Acadiana Colon Cancer Rates Among Nation’s Highest, Report Says

(The Advocate [Baton Rouge, LA]) Oct 12, 2014 - Colorectal cancer rates in the Acadiana region are among the nation’s highest, a health issue possibly linked to the region’s Cajun heritage, according to a study by the LSU Health New Orleans School of Public Health.
read article 



New Molecular Markers for Prostate Cancer Identified

(Sanford-Burnham Science Blog) Oct 9, 2014 - A team of scientists led by Sanford-Burnham’s Ranjan J Perera, Ph.D., has identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients, but not in normal healthy individuals.
read article 



Hormone Loss May be Involved in Colon Cancer, Study Says

(FoxNews.com) Oct 10, 2014 - Gene replacement therapy could hold promise in treating colon cancer, reveals a study published Friday in the journal Cancer, Epidemiology, Biomarkers & Prevention.
read article 



Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review

(Pfizer) Oct 13, 2014 - Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA).
read corporate press release 



CARs Motor Through Leukemia, Can 'Eradicate' Disease

(Medscape Medical News) Oct 13, 2014 - The remarkable results in leukemia patients treated with chimeric antigen receptor (CAR)-modified T-cells, which have caused such excitement among specialists treating hematologic malignancies, are now being published.
read article (free registration required) 



Got Insurance? You Still May Pay A Steep Price For Prescriptions

(Kaiser Health News) Oct 13, 2014 - Sandra Grooms recently got a call from her oncologist’s office. The chemotherapy drugs he wanted to use on her metastatic breast cancer were covered by her health plan, with one catch: Her share of the cost would be $976 for each 14-day supply of the two pills.
read article 



Doctors' Pay for Unapproved Prostate Cancer Device Raises Ethical Questions

(SFGate.com) Oct 12, 2014 - SonaCare Medical believes its treatment for prostate cancer is unusually precise and powerful, but the therapy faces a major obstacle: It is not approved in the United States.
read article 



NBC News Looks Into Possible Link Between Artificial Turf and Cancer

(Forbes) Oct 10, 2014 - NBC’s Nightly News aired scathing reports Wednesday and Thursday suggesting that artificial turf may cause cancer.
read article 



FDA Should Play Key Role in Lower Drug Costs

(The Hill/Congress blog) Oct 10, 2014 - Some big drug makers – protective of their profits – are fighting tooth and nail to roll back a provision of the ACA so that these drugs remain astronomically expensive – and inaccessible.
read article 



Big Data, Meet Big Money: NIH Funds Centers to Crunch Health Data

(Los Angeles Times) Oct 9, 2014 - Calling the world's wealth of health data a formidable "engine of discovery," the National Institutes of Health on Thursday awarded $32 million in grants in a bid to make huge biomedical data sets accessible to researchers the world over.
read article (free registration required) 



Pharma Sues Again Over Orphan Drug Discounts to Hospitals

(Wall Street Journal/Pharmalot blog) Oct 9, 2014 - An ongoing feud between the pharmaceutical industry and a federal agency over a discount drug program for certain hospitals is back in court.
read article (paid subscription required) 



“Fracking For the Cure”? Susan G. Komen Gets It All Wrong, Again

(SFGate.com/Notes & Errata blog) Oct 10, 2014 - Here’s a question: Is the Susan G. Komen breast cancer foundation insane?
read article 



PinnacleHealth Cancer Institute Expands Hematology/Oncology Program

(PinnacleHealth) Oct 9, 2014 - PinnacleHealth Cancer Institute welcomes three hematology/oncology specialists-- Irina Veytsman, MD, Jongming Li, PhD, MD and Sabrina Martyr, MD.
read press release 



5 Key Tips for Financial Advocates

(ACCCBuzz) Oct 10, 2014 - ACCCBuzz is in San Diego this week for the ACCC 31st National Oncology Conference.
read article 



Looking Back: 20 Years of Colorectal Cancer Treatment Breakthroughs Improve Survival, Advance Evidence-Based Choices

(NCCN) Oct 9, 2014 - The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual editions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon and Rectal Cancers, two of the eight original NCCN Guidelines® published in November 1996.
read press release 



Oxford Biomedica Strikes 'Transformational' $90m Deal With Novartis

(The Telegraph [UK]) Oct 10, 2014 - Swiss drug giant extends tie-up with British biotech for experimental cancer immunotherapy programme.
read article 



EU Agency Backs Continued Use of Ariad Leukaemia Drug

(Reuters) Oct 10, 2014 - European regulators said on Friday the benefits of Ariad Pharmaceuticals' leukaemia medicine Iclusig continued to outweigh its risks, but called for strengthened warnings on the product.
read article 



Medicare Recommends $500 Reimbursement For Exact Sciences' Colon Cancer Test

(TheStreet) Oct 10, 2014 - Medicare officials are recommending a $502 reimbursement for Exact Sciences' Cologuard colon cancer screening test, according to a preliminary payment report issued Thursday night.
read article 



Panobinostat FDA Review on Schedule, Novartis Says

(The Myeloma Beacon) Oct 9, 2014 - It seems that panobinostat’s review by the U.S. Food and Drug Ad­min­is­tra­tion (FDA) may be on track after all.
read article